These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18693162)

  • 1. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
    Mangana J; Zipser MC; Conrad C; Oberholzer PA; Cozzio A; Knuth A; French LE; Dummer R
    Eur J Dermatol; 2008; 18(5):566-70. PubMed ID: 18693162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
    Von Moos R; Cathomas R
    Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
    [No Abstract]   [Full Text] [Related]  

  • 4. [Liposomal doxorubicin and palmoplantar erythrodysesthesia].
    Tomb R; Stephan F; Halaby G
    Ann Dermatol Venereol; 2003 Nov; 130(11):1057-8. PubMed ID: 14724543
    [No Abstract]   [Full Text] [Related]  

  • 5. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
    Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
    Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
    Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
    Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
    Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
    Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions.
    Cady FM; Kneuper-Hall R; Metcalf JS
    Am J Dermatopathol; 2006 Apr; 28(2):168-72. PubMed ID: 16625083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe palmoplantar erythrodysesthesia and intertrigolike eruption induced by polyethylene glycol-coated liposomal doxorubicin.
    Campanelli A; Kerl K; Lübbe J
    J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):1022-4. PubMed ID: 16922969
    [No Abstract]   [Full Text] [Related]  

  • 10. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
    Rossi D; Catalano G
    Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
    [No Abstract]   [Full Text] [Related]  

  • 11. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
    Martschick A; Sehouli J; Patzelt A; Richter H; Jacobi U; Oskay-Ozcelik G; Sterry W; Lademann J
    Anticancer Res; 2009 Jun; 29(6):2307-13. PubMed ID: 19528496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
    von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
    Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.
    Mangili G; Petrone M; Gentile C; De Marzi P; Viganò R; Rabaiotti E
    Gynecol Oncol; 2008 Feb; 108(2):332-5. PubMed ID: 18083217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
    Markman M; Kulp B; Peterson G
    Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
    Risum S; Langer SW
    Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Rose PG
    Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
    Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
    von Gruenigen V; Frasure H; Fusco N; DeBernardo R; Eldermire E; Eaton S; Waggoner S
    Cancer; 2010 Oct; 116(20):4735-43. PubMed ID: 20629022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases].
    Hueso L; Sanmartín O; Nagore E; Botella-Estrada R; Requena C; Llombart B; Serra-Guillén C; Alfaro-Rubio A; Guillén C
    Actas Dermosifiliogr; 2008 May; 99(4):281-90. PubMed ID: 18394404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.